Skip to main content

Table 6 ACR50 and mPsARC response rates at week 12 in patients with PsA stratified by prior anti-TNF therapy

From: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

 

ACR50

mPsARC

 

Response rate,

Unadjusted odds ratio

Pvalue

Response rate,

Unadjusted odds ratio

Pvalue

 

n/N (%)

(95% CI)

 

n/N (%)

(95% CI)

 

History of prior anti-TNF therapy

      

   Prior ETN or IFX or both

25/60 (41.7)

0.65 (0.37 to 1.13)

0.130

42/59 (71.2)

0.66 (0.36 to 1.23)

0.194

   No prior ETN/IFXa

182/348 (52.3)

  

272/345 (78.8)

  
  1. aUsed as reference value. ACR50, American College of Rheumatology 50% or more improvement; CI, confidence interval; ETN, etanercept; IFX, infliximab; mPsARC, modified Psoriatic Arthritis Response Criteria; PsA, psoriatic arthritis.